Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 July 2021Next earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 109 min agoDividend
Analysts recommendations
Institutional Ownership
TNYA Latest News
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:
The average of price targets set by Wall Street analysts indicates a potential upside of 273.1% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 217.6% in Tenaya Therapeutics, Inc. (TNYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Two premium-laden buyouts sparked a wave of bargain hunting in biotech this week. Tenaya Therapeutics, a clinical-stage gene therapy company, was one of the industry's biggest winners.
What type of business is Tenaya Therapeutics?
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
What sector is Tenaya Therapeutics in?
Tenaya Therapeutics is in the Healthcare sector
What industry is Tenaya Therapeutics in?
Tenaya Therapeutics is in the Biotechnology industry
What country is Tenaya Therapeutics from?
Tenaya Therapeutics is headquartered in United States
When did Tenaya Therapeutics go public?
Tenaya Therapeutics initial public offering (IPO) was on 30 July 2021
What is Tenaya Therapeutics website?
https://www.tenayatherapeutics.com
Is Tenaya Therapeutics in the S&P 500?
No, Tenaya Therapeutics is not included in the S&P 500 index
Is Tenaya Therapeutics in the NASDAQ 100?
No, Tenaya Therapeutics is not included in the NASDAQ 100 index
Is Tenaya Therapeutics in the Dow Jones?
No, Tenaya Therapeutics is not included in the Dow Jones index
When was Tenaya Therapeutics the previous earnings report?
No data
When does Tenaya Therapeutics earnings report?
The next expected earnings date for Tenaya Therapeutics is 08 November 2024